Kowa announces first EU marketing authorisation for pitavastatin granted in the UK

Statin licenced to treat patients with primary hypercholesterolaemia or combined dyslipidemia

17.08.2010

Kowa announces first EU marketing authorisation for pitavastatin granted in the UK

Statin licenced to treat patients with primary hypercholesterolaemia or combined dyslipidemia

Wokingham, UK, 16 August 2010, Kowa are delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK licence for their statin, Livazo┬« (pitavastatin).This follows the completion of the decentralized regulatory procedure, in which the MHRA delivered a positive outcome for pitavastatin whilst acting as the Reference Member State for 16 EU countries. The UK licence represents the first national approval in the EU.  Pitavastatin is indicated for adults as an adjunctive therapy to diet for the treatment of primary hypercholesterolaemia or combined dyslipidemia.  It is available in doses of 1 mg, 2 mg and 4 mg

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X